Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy

Amino Acids

Volumn 43, Issue 4, 2012, Pages 1499-1507

  Zinellu, Angelo ^a,b   Sotgia, Salvatore ^b   Loriga, Giacomina ^c   Deiana, Luca ^b   Satta, Andrea Ercole ^c   Carru, Ciriaco ^b,d  

^a Porto Conte Ricerche Srl   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY HOSPITAL OF SASSARI   (Italy)

^d NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Chronic kidney disease; LDL; Oxidative stress; Taurine

Indexed keywords

ALLANTOIN; CYSTEINE; CYSTEINYLGLYCINE; EZETIMIBE; GLUTAMYLCYSTEINE; GLUTATHIONE; HOMOCYSTEINE; MALONALDEHYDE; SIMVASTATIN; TAURINE; THIOL DERIVATIVE; UNCLASSIFIED DRUG; URIC ACID;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MONOTHERAPY; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ALLANTOIN; AZETIDINES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; SIMVASTATIN; SULFHYDRYL COMPOUNDS; SUPEROXIDES; TAURINE; URIC ACID;

EID: 84867582461     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-012-1223-0     Document Type: Article

References (40)

1. Agarwal R (2004) Chronic kidney disease is associated with oxidative stress independent of hypertension. Clin Nephrol 61:377-383
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-Analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278
3. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J et al (2008) Oxidative stress and inflammation, Alink between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 111:S4-S9
4. Carru C, Deiana L, Sotgia S, Pes GM, Zinellu Aet al (2004) Plasma thiols redox status by laser-induced fluorescence capillary electrophoresis. Electrophoresis 25:882-889
5. Choi MJ, Kim JH, Chang KJ (2006) The effect of dietary taurine supplementation on plasma and liver lipid concentrations and free amino acid concentrations in rats fed Ahigh-cholesterol diet. Adv Exp Med Biol 583:235-242
6. Conard S, Bays H, Leiter LA, Bird S, Lin J, Hanson ME, Shah A, Tershakovec AM et al (2010) Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 12:210-218
7. Dembowski E, Davidson MH (2009) Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 16:183-188
8. Diepeveen SH, Verhoeven GH, van der Palen J, Dikkeschei BL, van Tits LJ, Kolsters G, Offerman JJ, Bilo HJ, Stalenhoef AF et al (2004) Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy. Nephron Clin Pract 98:c3-c7
9. Dierkes J, Westphal S, Luley C et al (2004) The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 3:101-111
10. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D et al (2006) Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 48:752-760
11. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'Neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA et al (2005) The target of ezetimibe is Niemann-Pick c1-like 1 (npc1l1). Proc Natl Acad Sci USA 102:8132-8137
12. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1370
13. Hansen SH, Andersen ML, Birkedal H, Cornett C, Wibrand F et al (2006) The important role of taurine in oxidative metabolism. Adv Exp Med Biol 583:129-135
14. Huxtable RJ (1992) Physiological actions of taurine. Physiol Rev 72:101-163
15. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, Shyr Y, Himmelfarb J et al (2002) Plasma F-isoprostane levels are elevated in chronic hemodialysis patients. Clinl Nephrol 58:190-197
16. Jong CJ, Azuma J, Schaffer S (2011) Mechanism underlying the antioxidant activity of taurine: prevention of mitochondrial oxidant production. Amino Acids. doi: 10.1007/s00726-011-0962-7
17. Kater AL, Batista MC, Ferreira SR (2010) Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects. Diabetol Metab Syndr 7:34-37
18. Kostapanos MS, Milionis HJ, Elisaf MS (2008) An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 13:157-174
19. Kostapanos MS, Spyrou AT, Tellis CC, Gazi IF, Tselepis AD, Elisaf M, Liberopoulos EN et al (2011) Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. Lipids 46:341-348
20. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ et al (2003) Level of kidney function as Arisk factor for cardiovascular outcomes in the elderly. Kidney Int 63:1121-1129
21. Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS et al (2003) Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 43:825-830
22. Murakami S, Sakurai T, Tomoike H, Sakono M, Nasu T, Fukuda N et al (2010) Prevention of hypercholesterolemia and atherosclerosis in the hyperlipidemia- and atherosclerosis-prone Japanese (LAP) quail by taurine supplementation. Amino Acids 38:271-278
23. Ong HT (2005) The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM 98:599-614
24. Puchades Montesa MJ, González Rico MA, Solís Salguero MA, Torregrosa Maicas I, Tormos Muñoz MC, Saez Tormo G, Juan Garcia I, Miguel Carrasco Aet al (2009) Study of oxidative stress in advanced kidney disease. Nefrologia 29:464-473
25. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW et al (2003) Kidney disease as Arisk factor for development of cardiovascular disease: Astatement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169
26. Schaffer SW, Azuma J, Mozaffari M (2009) Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol 87:91-99
27. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J et al (2003) ASCOT investigators, prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-Average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): Amulticentre randomised controlled trial. Lancet 361:1149-1158
28. Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, Seper C, Gimpelewicz CR (2008) Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with Ahistory of muscle-related side effects with other statins. Am J Cardiol 101:490-496
29. Suliman ME, Bárány P, Divino Filho JC, Qureshi AR, Stenvinkel P, Heimbürger O, Anderstam B, Lindholm B, Bergström J et al (2002) Influence of nutritional status on plasma and erythrocyte sulphur amino acids, sulph-hydryls, and inorganic sulphate in end-stage renal disease. Nephrol Dial Transpl 17:1050-1056
30. Suliman ME, Stenvinkel P, Bárány P, Heimbürger O, Anderstam B, Lindholm B (2003) Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. Am J Kidney Dis 41:S89-S95
31. Vaziri ND (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290:F262-F272
32. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drüeke T, Descamps-Latscha B et al (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524-2532
33. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C (2006) The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47:42-50
34. Yokogoshi H, Oda H (2002) Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed Ahigh-cholesterol diet. Amino Acids 23:433-439
35. Zinellu A, Carru C, Galistu F, Usai MF, Pes GM, Baggio G, Federici G, Deiana L (2003) N-methyl-d-glucamine improves the laser-induced fluorescence capillary electrophoresis performance in the total plasma thiols measurement. Electrophoresis 24:2796-2804
36. Zinellu A, Sotgia S, Scanu B, Chessa R, Gaspa L, Franconi F, Deiana L, Carru C (2009) Taurine determination by capillary electrophoresis with laser-induced fluorescence detection: from clinical field to quality food applications. Amino Acids 36:35-41
37. Zinellu A, Loriga G, Scanu B, Pisanu E, Sanna M, Deiana L, Satta AE, Carru C (2010) Increased low-density lipoprotein S-homocysteinylation in chronic kidney disease. Am J Nephrol 32:242-248
38. Zinellu A, Sotgia S, Deiana L, Carru C (2011a) Field-Amplified online sample stacking capillary electrophoresis UV detection for plasma malondialdehyde measurement. Electrophoresis 32:1893-1897
39. Zinellu A, Sotgia S, Deiana L, Carru C (2011b) Field-Amplified sample injection combined with pressure-Assisted capillary electrophoresis UV detection for the simultaneous analysis of allantoin, uric acid, and malondialdehyde in human plasma. Anal Bioanal Chem 399:2855-2861
40. Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G (2010) Adding Astatin to Acombination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol 299:F1203-F1211